1. Home
  2. IBRX vs AMRX Comparison

IBRX vs AMRX Comparison

Compare IBRX & AMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IBRX
  • AMRX
  • Stock Information
  • Founded
  • IBRX 2014
  • AMRX 2002
  • Country
  • IBRX United States
  • AMRX United States
  • Employees
  • IBRX N/A
  • AMRX N/A
  • Industry
  • IBRX Biotechnology: Biological Products (No Diagnostic Substances)
  • AMRX Biotechnology: Pharmaceutical Preparations
  • Sector
  • IBRX Health Care
  • AMRX Health Care
  • Exchange
  • IBRX Nasdaq
  • AMRX Nasdaq
  • Market Cap
  • IBRX 2.3B
  • AMRX 2.5B
  • IPO Year
  • IBRX N/A
  • AMRX N/A
  • Fundamental
  • Price
  • IBRX $2.81
  • AMRX $8.33
  • Analyst Decision
  • IBRX Strong Buy
  • AMRX Strong Buy
  • Analyst Count
  • IBRX 5
  • AMRX 4
  • Target Price
  • IBRX $11.40
  • AMRX $11.50
  • AVG Volume (30 Days)
  • IBRX 7.3M
  • AMRX 1.8M
  • Earning Date
  • IBRX 08-11-2025
  • AMRX 08-05-2025
  • Dividend Yield
  • IBRX N/A
  • AMRX N/A
  • EPS Growth
  • IBRX N/A
  • AMRX N/A
  • EPS
  • IBRX N/A
  • AMRX N/A
  • Revenue
  • IBRX $31,222,000.00
  • AMRX $2,830,186,000.00
  • Revenue This Year
  • IBRX $567.98
  • AMRX $9.84
  • Revenue Next Year
  • IBRX $160.56
  • AMRX $7.33
  • P/E Ratio
  • IBRX N/A
  • AMRX N/A
  • Revenue Growth
  • IBRX 10238.41
  • AMRX 13.42
  • 52 Week Low
  • IBRX $1.83
  • AMRX $6.50
  • 52 Week High
  • IBRX $7.48
  • AMRX $9.48
  • Technical
  • Relative Strength Index (RSI)
  • IBRX 51.33
  • AMRX 60.64
  • Support Level
  • IBRX $2.68
  • AMRX $8.22
  • Resistance Level
  • IBRX $3.00
  • AMRX $8.53
  • Average True Range (ATR)
  • IBRX 0.16
  • AMRX 0.21
  • MACD
  • IBRX -0.00
  • AMRX 0.01
  • Stochastic Oscillator
  • IBRX 62.00
  • AMRX 76.19

About IBRX ImmunityBio Inc.

ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.

About AMRX Amneal Pharmaceuticals Inc.

Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE - It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.

Share on Social Networks: